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2179with adenosine is insufﬁcient, and will underesti-
mate the hemodynamic signiﬁcance of most bridges.
Likewise, myocardial bridges cause signiﬁcant dia-
stolic pressure gradients, but normal or negative
systolic pressure gradients (systolic distal pressure,
Pd is greater than systolic proximal pressure, Pa)
as a result of systolic pressure overshooting. This
produces an artiﬁcial elevation in the mean pressure
used by traditional FFR, again resulting in an un-
derestimation of hemodynamic signiﬁcance. There-
fore, diastolic FFR with dobutamine challenge is
currently the technique of choice in testing for he-
modynamically signiﬁcant myocardial bridging. Of
note, the tracings used by the authors to demon-
strate hemodynamics in myocardial bridging
(Figure 7 in the paper by Corban et al.) (1), are
actually not consistent with expected pressure
tracings because the Pd is reduced compared with
the Pa. This suggests either an element of coronary
spasm or ﬁxed stenosis, rather than a signiﬁcant
myocardial bridge.
Second, as a novel noninvasive diagnostic tech-
nique, stress echocardiography has been shown to
identify myocardial bridges (3). Speciﬁcally, one sees
a unique wall motion abnormality of mid septal
buckling during peak stress, which distinguishes
itself from a ﬁxed left anterior descending (LAD)
artery stenosis by not involving the apex. We have
demonstrated that this ﬁnding of focal septal buck-
ling with apical sparing mirrors the hemodynamics
seen within and distal to the bridge. The most sig-
niﬁcant increases in ﬂow velocity and decreases in
diastolic pressure are almost invariably located
within the myocardial bridge, not distal to it as is
traditionally thought. We have postulated a Venturi-
like effect within the bridge, resulting in local (mid
septal) ischemia rather than distal ischemia.
Third, there is an ongoing misconception about
the location of plaque in relation to the myocardial
bridge. The maximal plaque burden is not at the
entrance of the bridge, but on average 20 mm to
30 mm proximal to the entrance of the bridge (3,4).
This may be attributable to the reversal of systolic
ﬂow seen on Doppler tracings, in which retrograde
ﬂow collides with antegrade ﬂow, causing high sys-
tolic wall shear stress (WSS) upstream from the
bridge entrance. The high systolic WSS referred to in
Figure 1 in the paper by Corban et al. (1) is actually
caused by external wall compression, not affecting
WSS inside the bridge. During diastole, the WSS is
low proximal and distal to the bridge, and even
lower within the bridge. Recognition of the location
of maximal plaque burden is important because it
has been shown that stents placed proximal to orextending into bridges have higher rates of target
lesion revascularization.
Finally, it should be clariﬁed that the “half-moon”
sign seen on intravascular ultrasound (IVUS) directly
corresponds to muscle tissue (5), not adipose tissue,
perivascular fat, or adventitia, as has been previously
suggested.*Jennifer A. Tremmel, MD, MS
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intravascular ultrasound and histology. Circ J 2014;78:502–4.REPLY: Myocardial BridgingWe appreciate the interest generated by our review
paper on myocardial bridging (1). In response
to comments by Dr. Tremmel and colleagues, we have
attempted to describe the complex pathophysiology
of myocardial bridging with emphasis on both systolic
and diastolic ﬂow abnormalities that can coexist with
atherosclerotic plaque proximal to the bridge, nega-
tive remodeling within the bridged segment, or
coronary vasospasm. We believe that it is reasonable
to begin the physiologic evaluation with fractional
ﬂow reserve (FFR) with adenosine administration
measured distal to a myocardial bridge. If abnormal,
this indicates concomitant ﬁxed obstruction from
either plaque proximal to the bridge, negative
remodeling within the bridge, or coronary vaso-
spasm. It is true that mean FFR measured within the
bridge may underestimate the maximal gradient as
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overshoot to the point of developing a negative sys-
tolic gradient. This phenomenon can also be observed
distal to the bridge, and diastolic FFR may unmask
larger gradients. The dobutamine challenge is per-
formed to interrogate the dynamic contribution of
increased contractility and tachycardia on the pres-
sure gradient. As with adenosine, dobutamine gradi-
ents in diastole may exceed those in systole because
of myocardial compression. The elegant paper by
Escaned et al. (2) demonstrated that combining
low-dose intracoronary adenosine (20 mg) with
moderate-dose intravenous dobutamine infusion
(20 mg/kg/min) increased the likelihood of unmasking
larger diastolic pressure gradients (5 of 12 patients).
Lin et al. (3) reported that diastolic FFR correlated
with septal buckling on exercise echocardiography in
14 patients. Another study of 18 patients with
myocardial bridging reported that dobutamine chal-
lenge was successfully performed in 13 of 18 patients.
Dobutamine-induced diastolic FFR did result in larger
gradients in 3 patients; however, it was not a pre-
dictor of major adverse cardiac events (4). Taken
together, it is clear that there are limited data corre-
lating diastolic FFR with adenosine, dobutamine, or
combined adenosine and dobutamine with noninva-
sive parameters of ischemia or clinical outcomes.
In our practice, when adenosine- and dobutamine-
induced FFR are negative, we test for coronary vaso-
spasm using intracoronary acetylcholine (off-label
use) as the demonstration of vasospasm without a
signiﬁcant bridge might be a scenario in which nitrate
therapy can be considered.
With regard to comments about wall shear stress
(WSS), any reversal of systolic ﬂow proximal to the
bridge that collides with antegrade ﬂow would not
lead to an increase in WSS. The momentum, which is
a vector quantity, of these opposing ﬂow ﬁelds would
result in a decrease in ﬂuid velocity at this location
and lower WSS values as we point out. Furthermore,
it should be noted that the higher pressure values
that have been measured proximal to a bridge would
lead to higher wall stress within the arterial tissue
(solid mechanics), assuming constant material prop-
erties, and not WSS, a ﬂuid induced mechanical
stress. Our computational ﬂuid dynamics simulations
(5) assume a rigid wall (i.e., no external myo-cardial
compression is included). Thus, the high WSS values
within the bridge observed in our ﬁgure are solely a
result of the lumen anatomy, both arterial radius and
curvature. Anatomy aside, the high WSS values
within the bridge should be expected on the basis of
clinical data. As has been reported (2), abnormal FFR
values within the myocardial bridge indicate thatintrabridge velocity values are higher (Bernoulli’s
principle), which would result in high WSS values as
compared with the proximal and distal regions.
We agree with Dr. Angelini that a thorough workup
to exclude concomitant atherosclerosis or vasospasm
can be valuable for patients with symptoms refractory
to medical therapy and that detailed physiologic
evaluation should be limited to centers with experi-
ence in the ﬁeld. As he indicates, although the
intravascular ultrasound (IVUS) “half-moon” sign is a
characteristic ﬁnding of myocardial bridges, the etiol-
ogy of the sign remains controversial. A recently pub-
lished autopsy image suggests that the echolucent
ﬁnding on IVUS might reﬂect a muscle band, although
the autopsy IVUS image in the paper may not be
characteristic of a clinically observed half-moon sign.
We also agree with Dr. Angelini that symptoms of chest
pain, myocardial infarction, and sudden death are
uncommon relative to the prevalence of myocardial
bridging and that correlating symptomswith data from
diagnostic testing to identifywhether or not symptoms
are related to myocardial bridging, concomitant vaso-
spasm, atherosclerosis, or none of the preceding is
often challenging. Large prospective registries are
warranted to better deﬁne the role of myocardial
bridging in symptoms, ﬂow disturbances, endothelial
dysfunction, atherosclerosis development, and prog-
nosis of these patients.Michel T. Corban, MD
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Mysterious Regulator
in Myocardial Fibrosis
and Circulating miR-29a
as a BiomarkerMyocardial ﬁbrosis is characterized by pathological
modiﬁcation of myocardium, in which cardiomyo-
cytes undergo apoptosis and the heart tissue is
replaced by ﬁbroblasts; this phenomenon is usually
referred to as cardiac remodeling. However, the
pathogenesis of myocardial ﬁbrosis is still unclear
despite advances in our understanding of the
ischemic process.
MicroRNAs (miRs), small endogenous noncoding
RNAs, have a well-documented role in the regulation
of the cardiovascular system. miRs such as miR-29
and miR-21 have been shown to have a role in the
genesis of myocardial ﬁbrosis.
Roncarati et al. (1) measured a set of miRs in the
plasma of patients with hypertrophic cardiomyopathy
to understand which miRs can be regarded as bio-
markers of this disease. Only miR-29a levels were
found to correlate with cardiac ﬁbrosis, along with
several miRs related to cardiac hypertrophy. This
discovery is signiﬁcant in that it may help deﬁne
patients who may develop ﬁbrosis. However, it is
important to know where miR-29a comes from and
what types of cells, cardiomyocytes or ﬁbroblasts,
secrete it. Previous studies have shown the opposite
effect of miR-29 in different types of cells (2–5).
On one hand, miR-29 can promote cardiomyocyte
apoptosis via down-regulation of antiapoptosis
genes, such as Bcl-2, CDC42, and Tcl-1 (2–4); on the
other hand, miR-29 can protect against ﬁbrosis
through inhibition of collagens released from ex-
tracellular matrix (5). Because the majority of
cell types change from cardiomyocyte to myoﬁ-
broblast phenotype during progression of cardiac
remodeling, it is reasonable to hypothesize that
up-regulation of miR-29a in the plasma of these pa-
tients is mainly due to cardiomyocyte apoptosis and
not secretion from ﬁbroblasts. It is also possible that
the up-regulation of miR-29a in plasma reﬂects thebody’s attempt to express more ﬁbrosis-protective
mediators to prevent adverse cardiac remodeling.
Cardiac remodeling is a complicated process that
involves a number of molecular and pathological
alterations (5). A simple measurement of miRs at one
time point may not be enough to deﬁne molecular
changes. Identiﬁcation of miR-29a (and other miRs) in
different cell types and at different time points is
necessary before recognizing it as a biomarker for
cardiac remodeling.Yao Dai, MD
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Regulator in Myocardial Fibrosis and
Circulating miR-29a as a BiomarkerWe thank Dr. Dai and colleagues for their interest in
our paper (1). As their letter suggests, it is possible that
microRNA (miR)-29 is secreted by more than one cell
type. However, our intention was not to address this
question, which has been partly done and should be
tackled further in other settings and with appropriate
technologies (tissue-speciﬁc knockout mice, trans-
genic mice, and so on); we simply found a signiﬁcant
correlation between a few circulating miRs, in par-
ticular miR-29a, and the degree of cardiac ﬁbrosis
in patients with hypertrophic cardiomyopathy.
We therefore agree with the concept expressed in
the letter by Dr. Dai and colleagues that miR-29s are
expressed in many cell types, where it probably plays
